Evaluation of the central and peripheral components for induction of postural hypotension by guanethidine, clonidine, dopamine2 receptor agonists and 5-hydroxytryptamine1A receptor agonists.
Previously, it was observed that the severity of postural hypotension in rats after i.v. administration is: guanethidine (severe) greater than clonidine greater than dopamine2 (DA2) receptor agonists greater than 5-hydroxytryptamine1A (5-HT1A) receptor agonists (none). In this paper we investigated central and peripheral mechanisms involved in postural hypotension induced by these drugs. Intracerebroventricular or intracisternal doses of the above agents produced a fall in mean arterial pressure of 32 to 42 mm Hg and were used for evaluation of the central component. Intracerebroventricular, but not intracisternal, clonidine induced postural hypotension. DA2 or 5-HT1A receptor agonists did not induce postural hypotension after either i.c.v. or intracisternal administration. Intracerebroventricular guanethidine did not lower arterial pressure dose-dependently, or did it produce postural hypotension. A peripheral action postulated to be involved in the postural hypotension was inhibition of sympathetic neurotransmission; to evaluate this inhibition, drug effects on pressor and tachycardiac responses elicited by electrical stimulation in pithed rats were determined. Inhibition of heart rate changes by each of the drugs was: guanethidine, 60 to 100% at 0.1 to 8.0 Hz; clonidine, 20 to 40% at 0.1 to 2.0 Hz; DA2 receptor agonists, 10 to 45% at 0.1 to 2.0 Hz; and 5-HT1A receptor agonists, 20 to 40% at less than or equal to 0.5 Hz. These data indicate that the frequency selective inhibition in the peripheral sympathetic nervous system may explain the likelihood of postural hypotension for guanethidine, clonidine DA2 and 5-HT1A receptor agonists. Clonidine has some central component for induction of postural hypotension in addition to the frequency-related peripheral component.
Park
K H
KH
Department of Pharmacology, College of Medicine, University of Iowa, Iowa City.
Long
J P
JP
Cannon
J G
JG
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D001919:Bradycardia / Q000139:chemically induced; D002415:Cats; D002490:Central Nervous System / Q000187:drug effects / Q000502:physiology*; D003000:Clonidine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005260:Female; D006145:Guanethidine / Q000494:pharmacology*; D007024:Hypotension, Orthostatic / Q000139:chemically induced* / Q000503:physiopathology; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012018:Reflex / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology*
D011954:Receptors, Dopamine; D011985:Receptors, Serotonin; D003000:Clonidine; D006145:Guanethidine